Purple Biotech Ltd.
Simbol: PPBT
NASDAQ
0.67
USDTržna cena danes
-0.6807
Razmerje P/E
-0.0254
Razmerje PEG
17.38M
Kapaciteta MRK
- 0.00%
Donos DIV
Purple Biotech Ltd. (PPBT) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 73.01 | 15.4 | 32.1 | 47.2 | |||||||||||
balance-sheet.row.short-term-investments | 4.34 | 0.9 | 17.1 | 36.3 | |||||||||||
balance-sheet.row.net-receivables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.inventory | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-current-assets | 3.29 | 0.4 | 1.1 | 1.3 | |||||||||||
balance-sheet.row.total-current-assets | 76.3 | 15.8 | 33.3 | 48.5 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 2.18 | 0.5 | 0.7 | 0.9 | |||||||||||
balance-sheet.row.goodwill | 112.06 | 28 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0.11 | 0 | 20.7 | 20.5 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 112.18 | 28 | 20.7 | 20.5 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0.2 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 0 | 0 | 0 | 0.2 | |||||||||||
balance-sheet.row.total-non-current-assets | 114.36 | 28.5 | 21.4 | 21.7 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 190.66 | 44.3 | 54.6 | 70.2 | |||||||||||
balance-sheet.row.account-payables | 10.15 | 3.5 | 2.1 | 1.5 | |||||||||||
balance-sheet.row.short-term-debt | 0.74 | 0.2 | 0.2 | 0.2 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 0.87 | 0.2 | 0.3 | 0.6 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 13.01 | 3.5 | 4.7 | 2.6 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 3.95 | 2.8 | 0.5 | 0.8 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 1.42 | 0.2 | 0.5 | 0.7 | |||||||||||
balance-sheet.row.total-liab | 27.85 | 10 | 7.5 | 5.1 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -520.12 | -137.5 | -117.6 | -95.9 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 69.19 | 38.5 | 10.1 | 8.8 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 613.23 | 133.2 | 154.4 | 152 | |||||||||||
balance-sheet.row.total-stockholders-equity | 162.29 | 34.2 | 46.9 | 64.8 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 190.66 | 44.3 | 54.6 | 70.2 | |||||||||||
balance-sheet.row.minority-interest | 0.51 | 0.1 | 0.2 | 0.3 | |||||||||||
balance-sheet.row.total-equity | 162.81 | 34.3 | 47.1 | 65.1 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 190.66 | - | - | - | |||||||||||
Total Investments | 4.34 | 0.9 | 17.1 | 36.5 | |||||||||||
balance-sheet.row.total-debt | 1.61 | 0.4 | 0.5 | 0.7 | |||||||||||
balance-sheet.row.net-debt | -67.07 | -14.1 | -14.5 | -10.1 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -19.95 | -19.9 | -21.8 | -17.8 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0.2 | 0.2 | 0.2 | 0.2 | |||||||||||
cash-flows.row.deferred-income-tax | 0.64 | -0.8 | 0 | 0 | |||||||||||
cash-flows.row.stock-based-compensation | 1.88 | 1.9 | 2.4 | 2.1 | |||||||||||
cash-flows.row.change-in-working-capital | 0.27 | 0.3 | 3.3 | 0.6 | |||||||||||
cash-flows.row.account-receivables | 0 | 0.2 | 0.3 | -0.3 | |||||||||||
cash-flows.row.inventory | 0 | 0 | 0 | 0.6 | |||||||||||
cash-flows.row.account-payables | 1.33 | 1.3 | 0.8 | 0.3 | |||||||||||
cash-flows.row.other-working-capital | -1.06 | -1.2 | 2.1 | 0 | |||||||||||
cash-flows.row.other-non-cash-items | -2.9 | -0.9 | -0.8 | -0.1 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -19.86 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -0.2 | -0.1 | |||||||||||
cash-flows.row.acquisitions-net | -3.55 | -3.5 | 0 | 0 | |||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 16.68 | 16.7 | 19.8 | 13.2 | |||||||||||
cash-flows.row.other-investing-activites | 0.67 | 0 | 0.3 | 0.4 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 13.8 | 13.1 | 19.9 | 13.4 | |||||||||||
cash-flows.row.debt-repayment | -0.17 | -0.2 | -0.2 | -0.2 | |||||||||||
cash-flows.row.common-stock-issued | 5.86 | 5.7 | 1.5 | 0.6 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | -0.93 | -0.9 | -0.2 | 1.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 5.46 | 5.5 | 1.1 | 1.5 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0.05 | 0.1 | -0.2 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -0.54 | -0.5 | 4.1 | -0.4 | |||||||||||
cash-flows.row.cash-at-end-of-period | 68.68 | 14.5 | 15 | 10.9 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 69.22 | 15 | 10.9 | 11.2 | |||||||||||
cash-flows.row.operating-cash-flow | -19.86 | -19.2 | -16.7 | -15.1 | |||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -0.2 | -0.1 | |||||||||||
cash-flows.row.free-cash-flow | -19.86 | -19.2 | -17 | -15.2 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 0 | -0.9 | -0.3 | |||||||||||
income-statement-row.row.cost-of-revenue | 0.2 | 0.2 | 0.2 | 0.2 | |||||||||||
income-statement-row.row.gross-profit | -0.2 | -0.2 | -1.1 | -0.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 17.03 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 22.22 | 22.1 | 22.6 | 17.9 | |||||||||||
income-statement-row.row.cost-and-expenses | 22.27 | 22.3 | 22.6 | 17.9 | |||||||||||
income-statement-row.row.interest-income | 0.47 | 0.5 | 1 | 0.3 | |||||||||||
income-statement-row.row.interest-expense | 2.19 | 2.2 | 0.1 | 0.2 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -7.98 | 2.3 | 0.8 | 0.1 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | -7.98 | 2.3 | 0.8 | 0.1 | |||||||||||
income-statement-row.row.interest-expense | 2.19 | 2.2 | 0.1 | 0.2 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0.47 | 0.2 | 1.2 | 0.6 | |||||||||||
income-statement-row.row.ebitda-caps | -20.96 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -12 | -22.3 | -22.6 | -17.9 | |||||||||||
income-statement-row.row.income-before-tax | -19.98 | -20 | -21.8 | -17.8 | |||||||||||
income-statement-row.row.income-tax-expense | -9.54 | -0.1 | -0.9 | 0.6 | |||||||||||
income-statement-row.row.net-income | -19.88 | -19.9 | -20.8 | -18.5 |
Pogosto zastavljeno vprašanje
Kaj je Purple Biotech Ltd. (PPBT) skupna sredstva?
Purple Biotech Ltd. (PPBT) skupna sredstva so 44302000.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so N/A.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.000.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je -0.807.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je 0.000.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so 0.000.
Kaj je Purple Biotech Ltd. (PPBT) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je -19880000.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 351000.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 22072000.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 14489000.000.